Ameriprise
ANAB icon

Ameriprise’s AnaptysBio ANAB Stock Holding History

Ameriprise’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-44,919
Closed -$807K – 3899
2023
Q3 		$807K Sell
44,919
-42,947
-49% -$820K ﹤0.01% 3233
2023
Q2 		$1.79M Buy
87,866
+1,035
+1% +$21K ﹤0.01% 2929
2023
Q1 		$1.89M Buy
86,831
+34,426
+66% +$837K ﹤0.01% 2873
2022
Q4 		$1.62M Sell
52,405
-885
-2% -$25K ﹤0.01% 2902
2022
Q3 		$1.36M Sell
53,290
-1,488
-3% -$34.9K ﹤0.01% 2966
2022
Q2 		$1.11M Sell
54,778
-599
-1% -$13.3K ﹤0.01% 3075
2022
Q1 		$1.37M Buy
55,377
+12,902
+30% +$390K ﹤0.01% 3075
2021
Q4 		$1.48M Buy
+42,475
New +$1.35M ﹤0.01% 3079
2020
Q3 		– Sell
-12,469
Closed -$279K – 3727
2020
Q2 		$279K Buy
+12,469
New +$228K ﹤0.01% 3382

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Ameriprise's ANAB Position: Q4 2023 in Review

Ameriprise sold out of AnaptysBio (ANAB) in Q4 2023, closing a stake of 44,919 shares — an estimated $807K sold.

Ameriprise first reported a position in ANAB in Q2 2020 and held it in 9 quarters. The position peaked at $1.89M in Q1 2023. 119 funds tracked by Wall St. Rank hold ANAB as of Q4 2023.

  • Ameriprise reported no remaining AnaptysBio position as of Q4 2023 after selling out during the quarter.
  • Ameriprise sold 44,919 AnaptysBio shares in Q4 2023, an estimated $807K.
  • Ameriprise first reported a position in AnaptysBio in Q2 2020 and held it in 9 quarters.
  • Ameriprise's AnaptysBio position peaked at $1.89M in Q1 2023.
  • 119 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2023.

Based on Ameriprise's 13F filing for Q4 2023, filed 14 Feb 2024.